In particular, consistent with the above reported observation that RB1 knockdown enhances the sensitivity to cell death induced by DNA-damaging agents in breast cancer cells [47], the disruption of RB1 function was found to be associated with improved response to adjuvant/neoadjuvant chemotherapy and good clinical outcome for patients with breast cancer [101–104]. Here, RB1 is linked to breast carcinoma.